XBiotech Inc. (XBIT)

USD 6.09

(-9.64%)

Market Cap (In USD)

185.64 Million

Revenue (In USD)

-

Net Income (In USD)

-24.55 Million

Avg. Volume

104.94 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.81-9.96
PE
-
EPS
-
Beta Value
1.413
ISIN
CA98400H1029
CUSIP
98400H102
CIK
1626878
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. John Simard
Employee Count
-
Website
https://www.xbiotech.com
Ipo Date
2015-04-15
Details
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.